高危前列腺癌高剂量率近距离治疗联合外照射放疗后十年生存:与挪威SPCG-7队列的比较
本研究比较高危前列腺癌患者接受高剂量率近距离治疗联合外照射放疗(HDR-BT/EBRT,计算EQD2=102 Gy)与单纯外照射放疗(70 Gy)的10年前列腺癌特异性死亡率和总死亡率。结果显示联合治疗组前列腺癌特异性死亡风险降低3.6倍,总死亡风险降低1.6倍,Gleason评分8-10与前列腺癌特异性死亡率独立相关。作者认为需开展随机研究。
要点
- 高危前列腺癌HDR-BT/EBRT组10年前列腺癌特异性死亡率为2.5%,单纯EBRT组为8.2%。
- HDR-BT/EBRT组10年总死亡率为16%,单纯EBRT组为23%。
- 治疗方式(HR=3.59)和Gleason评分(HR=2.48)与前列腺癌特异性死亡率相关。
核心结论
- 高危前列腺癌患者接受HDR-BT/EBRT剂量递增放疗较单纯EBRT(70 Gy)显著降低前列腺癌特异性死亡率和总死亡率。
- Gleason评分8-10与前列腺癌特异性死亡风险增加独立相关。
- 作者认为需开展随机研究。
研究设计与样本
- 观察性研究,比较HDR-BT/EBRT组(N=325)与历史对照组(N=296)的10年生存。
- HDR-BT/EBRT组接受HDR-BT boost(10 Gy×2,间隔2周)后行50 Gy适形EBRT(2 Gy×25)照射前列腺和精囊,并接受中位2年雄激素剥夺治疗。
- 历史对照组接受中位70 Gy(2 Gy×35)照射前列腺和精囊,并接受终身抗雄激素治疗。
- 采用竞争风险分析和Kaplan-Meier分析分别评估前列腺癌特异性死亡率和总死亡率,logrank检验比较差异,Cox回归分析独立关联,显著性水平p<0.05。
主要发现
- 中位随访时间HDR-BT/EBRT组为104个月,EBRT组为120个月。
- HDR-BT/EBRT组较单纯EBRT组前列腺癌特异性死亡风险降低3.6倍(p<0.01),总死亡风险降低1.6倍(p=0.02)。
- 10年总死亡率和前列腺癌特异性死亡率HDR-BT/EBRT组分别为16%和2.5%,单纯EBRT组分别为23%和8.2%。
- 治疗方式(HR=3.59,95%CI 1.50-8.59)和Gleason评分(HR=2.48,95%CI 1.18-5.21)与前列腺癌特异性死亡率相关。
- 仅治疗方式(HR=1.63,95%CI 1.08-2.44)与总死亡率显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需开展随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The survival benefit of dose-escalation with High-Dose-Rate brachytherapy (HDR-BT) boost combined with External Beam Radiotherapy (EBRT) for the treatment of high-risk prostate cancer (PCa) remains debatable. We investigated 10-year PCa-specific mortality (PCSM) and overall mortality (OM) in high-risk patients treated with HDR-BT/EBRT (calculated EQD2 = 102 Gy) compared to EBRT alone (70 Gy). METHODS: HDR-BT boosts (10 Gy × 2) were given 2 weeks apart followed by 50 Gy conformal EBRT (2 Gy × 25) to the prostate and seminal vesicles. The HDR-BT/EBRT group (N:325) received Androgen Deprivation Therapy for a median duration of 2 years. The historical control group (N:296), received a median dose of 70 Gy (2 Gy × 35) to the prostate and seminal vesicles with lifelong Anti-Androgen Treatment. For each treatment group PCSM and OM were established by competing-risk analyses and Kaplan-Meier analyses respectively. Differences were evaluated by the logrank test. Independent associations were established by Cox regression analyses. Significance level set to p < 0.05. RESULTS: Median follow-up was 104 and 120 months for the HDR-BT/EBRT and the EBRT group respectively. A 3.6-fold decreased risk of PCSM (p < 0.01) and a 1.6-fold decreased risk of OM (p = 0.02) in the HDR-BT/EBRT cohort compared to the EBRT-only group were revealed. Ten-year OM and PCSM rates were 16% and 2.5% in the HDR-BT/EBRT group versus 23% and 8.2% in the EBRT-only group respectively. Both treatment modality (HR = 3.59, 95%CI 1.50-8.59) and Gleason score (HR = 2.48, 95%CI 1.18-5.21) were associated with PCSM. Only treatment modality (HR = 1.63, 95%CI = 1.08-2.44) was significantly associated with OM. CONCLUSIONS: Men with high-risk PCa have a significantly reduced PCSM and OM rates when treated with dose-escalated radiotherapy achieved by HDR-BT/EBRT compared to EBRT alone (70 Gy). A Gleason score of 8-10 was independently associated with increased risk of PCSM. Randomized studies are warranted. SUMMARY: Observational study of 10-year survival in high-risk Prostate Cancer (PCa) after High-Dose-Rate brachytherapy combined with External Beam Radiation Therapy (HDR-BT/EBRT) compared to EBRT alone. The combined HDR-BT/EBRT treatment was found to give a 3.6-fold decrease in Prostate Cancer Specific Mortality (PCSM) and a 1.6-fold decrease in Overall Mortality (OM). Gleason score and type of treatment strongly influenced PCSM whereas only treatment modality was associated with OM. The observed benefits of dose-escalation warrant future randomized trials.
引用
- Wedde TB, Småstuen MC, Brabrand S, et al. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. Radiother Oncol. 2018. PMID: 30389241. doi:10.1016/j.radonc.2018.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。